Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Innovent Medical Solutions Ltd.

This article was originally published in Start Up

Executive Summary

Ventilator associated pneumonia (VAP), the second most common infection in the ICU, is caused when infected secretions that accumulate in and around the endotracheal tube leak into the lungs. Innovent Medical Solutions Ltd. intends to reduce both the incidence and the cost of treating VAP with noninvasive technology that mimics nature's own method for clearing airways: the cough. T In addition to decreasing the number of VAP cases by 50%, the company thinks its technology will also facilitate more use of noninvasive facemask ventilation, leading to an improvement in the quality of life for ICU patients.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts